Objective: The purpose of this study was to determine the relationship between cerebral blood flow (CBF) measurements in acute stroke and early clinical outcome. Material and Methods: The xenon-enhanced computed tomography (XeCT) CBF studies performed in 50 patients in the acute stage (within 8 h) of a hemispheric stroke were retrospectively analyzed. The mean CBF of the symptomatic vascular territory was compared to the corresponding territory in the contralateral hemisphere. Clinical assessment on admission and discharge was performed using the National Institutes of Health stroke scale (NIHSS). Results: Three groups were defined according to the degree of CBF asymmetry between the symptomatic and the contralateral asymptomatic vascular region. The CBF asymmetry was mild in group A (≤20%), moderate in group B (>20% and <60%) and severe in group C (≥60%). Patients in group A (n = 18) had a good outcome with a mean NIHSS score of 2 ± 2 at discharge. In group B, the patients (n = 22) had intermediate but variable outcomes: 2 patients died and the mean NIHSS score for the survivors was variable (mean NIHSS score: 9 ± 6). The patients in group C (n = 10) had a very poor outcome: 4 patients died and the survivors had a mean NIHSS score of 15 ± 1. Conclusions: Quantitative XeCT CBF measurements may be useful for selecting subgroups of stroke patients with different clinical outcomes. The possibility of predicting patient prognosis as early as in the first hours after the ischemic event may help to identify the appropriate target population that will benefit from aggressive stroke therapy.

Keywords:
Stroke, Cerebral blood flow, Xenon-enhanced computed tomography, Prognosis
1.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
2.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.
3.
Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J, for the Lubeluzole International Study Group: Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke 1996;27:76–81.
4.
Giubilei F, Lenzi GL, Di Piero V, Pozzilli C, Pantano P, Bastianello S, Argentino C, Fieschi C: Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke. Stroke 1990;21:895–900.
5.
Hanson SK, Grotta JC, Rhoades H, Tran HD, Lamki LM, Barron BJ, Taylor WJ: Value of single-photon emission-computed tomography in acute stroke therapeutic trials. Stroke 1993;24:1322–1329.
6.
Alexandrov AV, Bladin CF, Elrich LE, Norris JW: Noninvasive assessment of intracranial perfusion in acute cerebral ischemia. J Neuroimag 1995;5:76–82.
7.
Shimosegawa E, Hatazawa J, Atsusi I, Fujita H, Ogawa T, Aizawa Y, Kanno I, Okudera T, Uemura K: Cerebral infarction within six hours of onset: Prediction of completed infarction with technetium-99m-HMPAO SPECT. J Nucl Med 1994;35:1097–1103.
8.
Alexandrov AV, Black SE, Ehrlich LE, Bladin CF, Smurawska LT, Pirisi A, Caldwell CB: Simple visual analysis of brain perfusion on HMPAO SPECT predicts early outcome in acute stroke. Stroke 1996;27:1537–1542.
9.
Laloux P, Richelle F, Jamart J, De Coster P, Laterre C: Comparative correlations of HMPAO SPECT indices, neurological score, and stroke subtypes with clinical outcome in acute carotid infarcts. Stroke 1995;26:816–821.
10.
Marchal G, Serrati C, Rioux P, Petit-Taboue MC, Viader F, de la Sayette V, Le Doze F, Lochon P, Derlon JM, Orgogozo JM, Baron JC: PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet 1993;341:925–927.
11.
Limburg M, van Royen EA, Hijdra A, de Bruine JF, Verbeeten BWJ: Single-photon emission computed tomography and early death in acute ischemic stroke. Stroke 1990;21:1150–1155.
12.
Alexandrov AV, Elrich LE, Bladin CF, Norris JW: Cerebral perfusion index: A new marker for clinical outcome in acute stroke. J Neuroimag 1993;3:209–215.
13.
Bowler JV, Wade JPH, Jones BE, Nijran K, Steiner MB: Single-photon emission computed tomography using hexamethylpropyleneamine oxime in the prognosis of acute cerebral infarction. Stroke 1996;27:82–86.
14.
Limburg M, van Royen EA, Hijdra A, Verbeeten B: rCBF-SPECT in brain infarction: When does it predict outcome. J Nucl Med 1991;32:382–387.
15.
Lee RGL, Hill TC, Holman L, Royal HD, O’Leary D, Clouse ME: Predictive value of perfusion defect size using N-isopropyl-(I-123)-p-iodoamphetamine emission tomography in acute stroke. J Neurosurg 1984;61:449–452.
16.
Mountz JM, Modell JG, Foster NL, DuPree ES, Ackermann RJ, Petry NA, Bluemlein LE, Kuhl DE: Prognostication of recovery following stroke using the comparison of CT and technetium-99m HM-PAO SPECT. J Nucl Med 1990;31:61–66.
17.
Powers WJ, Grubb RL, Raichle ME: Physiological response to focal cerebral ischemia in humans. Ann Neurol 1984;16:546–552.
18.
Brott TG, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Herzberg V, Rorick M, Moomaw CJ, Walker M: Measurement of acute cerebral infarction: A clinical examination scale. Stroke 1989;20:864–870.
19.
Kety SS, Schmidt CF: The nitrous oxide method for the quantitative determination of cerebral blood flow in man: Theory, procedure, and normal values. J Clin Invest 1948;27:476–483.
20.
Gur D, Good WF, Wolfson SK Jr, Yonas H, Shabason L: In vivo mapping of local cerebral blood flow by xenon-enhanced computed tomography. Science 1982;215(5):1267–1268.
21.
Bryan RN, Levy LM, Whitlow WD, Killian JM, Preziosi TJ, Rosario JA: Diagnosis of acute cerebral infarction: comparison of CT and MR imaging. AJNR 1992;12:611–620.
22.
Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L: Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91:311–322.
23.
Yokogami K, Nakano S, Ohta H, Goya T, Wakisaka S: Prediction of hemorrhagic complication after thrombolytic therapy for middle cerebral artery occlusion: Value of pre- and post-therapeutic computed tomographic findings and angiographic occlusive site. Neurosurgery 1996;39:1102–1107.
24.
Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W: Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167–1174.
25.
Firlik AD, Kaufmann AM, Wechsler LR, Firlik K, Fukui MB, Yonas H: Quantitative cerebral blood flow determinations in acute ischemic stroke: Relationship to computed tomography and angiography. Stroke 1997;28:2208–2213.
26.
Bozzao L, Bastianello S, Fantozzi LM, Angeloni U, Argentino C, Fieschi C: Correlation of angiographic and sequential CT findings in patients with evolving cerebral infarction. AJNR 1989;10:1215–1222.
27.
Hughes RL, Yonas H, Gur D, Latchaw R: Cerebral blood flow determination within the first 8 hours of cerebral infarction using stable xenon-enhanced computed tomography. Stroke 1989;20:754–760.
28.
Dierckx RA, Dobbeleir A, Pickut BA, Timmermans L, Dierckx I, Vervaet A, Vandevivere J, Deberdt W, De Deyn PP: Technetium-99m HMPAO SPECT in acute supratentorial ischaemic infarction expressing deficits as millilitre of zero perfusion. Eur J Nucl Med 1995;22:427–433.
29.
Hayman LA, Taber KH, Jhingran SG, Killian JM, Carroll RG: Cerebral infarction: Diagnosis and assessement of prognosis by using 123IMP-SPECT and CT. AJNR 1989;10:557–562.
30.
Davis SM, Chua MG, Lichtenstein M, Rossiter SC, Binns D, Hopper JL: Cerebral hypoperfusion in stroke prognosis and brain recovery. Stroke 1993;24:1691–1696.
31.
Olsen TS, Lassen NA: A dynamic concept of middle cerebral artery occlusion and cerebral infarction in the acute state based on interpreting severe hyperemia as a sign of embolic migration. Stroke 1984;15:458–468.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.